Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biologics Approval Time Drops To 19 Months In 2001

Executive Summary

The average approval time for a new therapeutic/ vaccine biologic application in 2001 was 19 months, a five-month improvement over 2000

You may also be interested in...



FDA Drug Approval Time Edges Up To 18.5 Months In 2001

The average NDA approval time is still about a year and a half, an analysis of new molecular entities cleared by FDA in 2001 shows

CBER User Fee Standards May Need To Differ From CDER's, Director Zoon Says

The Center for Biologics Evaluation & Research may need a different set of user fee review parameters than the drug center, CBER Director Kathryn Zoon, PhD, suggested during a Dec. 7 FDA public meeting on the Prescription Drug User Fee Act

Lilly Xigris Price Is $6,800 Per Dose; Sepsis Agent Clears FDA

Lilly's sepsis agent Xigris will be priced at an average net wholesale price of $6,800 per 96-hour course of therapy, depending on the weight of the patient

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel